HCPLive

Exposure to Tamoxifen Causes CNS Cell Death

 
THURSDAY, Sept. 19 (HealthDay News) -- Tamoxifen causes central nerve system (CNS) cell cytotoxicity, and MEK1/2 inhibition can prevent tamoxifen-induced cell death, according to a study published in the Sept. 18 issue of The Journal of Neuroscience.

Hsing-Yu Chen, from the University of Rochester Medical School in New York, and colleagues examined the impact of exposure to tamoxifen on CNS cell populations.

The researchers found that, in vitro, tamoxifen was cytotoxic for various CNS cell populations, and it was associated with increased cell death in the corpus callosum. In addition, tamoxifen was associated with reduced cell division in the mouse subventricular zone, the hippocampal dentate gyrus, and the corpus callosum. In vitro, MEK1/2 inhibition selectively rescued primary glial progenitors from tamoxifen cytotoxicity, while simultaneously enhancing the effect of tamoxifen on MCF7 luminal human breast cancer cells. In systematically treated mice, in vivo MEK1/2 inhibition prevented tamoxifen-induced cell death.

"Our results demonstrate unexpected cytotoxicity of this putatively benign anti-hormonal agent and offer a potential strategy for rescuing CNS cells from adverse effects of tamoxifen," the authors write.

Abstract 

Full Text (subscription or payment may be required) 

Copyright © 2013 HealthDay. All rights reserved.
 
 
 

Most Popular

Recommended Reading

Programmed cell death 1 inhibition with pembrolizumab is showing early promise for some patients with advanced non-small-cell lung cancer, according to preliminary findings published online April 19 in the New England Journal of Medicine. The research was published to coincide with the annual meeting of the American Association for Cancer Research, held from April 18 to 22 in Philadelphia.
A gene variation associated with smoking longer and getting lung cancer at a younger age has been identified by researchers. The study was published in the May issue of the Journal of the National Cancer Institute.
Longer nighttime fasting duration is associated with improved glycemic regulation, and in turn, may reduce a woman's risk for breast cancer by improving biomarkers of glycemic control. The findings were published online April 20 in Cancer Epidemiology, Biomarkers & Prevention to coincide with the annual meeting of the American Association for Cancer Research, held from April 18 to 22 in Philadelphia.
Compared to white men, black men appear to have up to four-fold greater risk of developing prostate cancer as their body mass index increases, according to a study published online April 16 in JAMA Oncology.
$vAR$